ABVC BioPharmaABVC 17 3-1 Month Momentum % is -5.63% as of Jul. 09, 2026. GuruFocus rates ABVC with a GF Score™ of 17/100 and a GF Value™ of $0.87 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,378 Biotechnology companies, ABVC BioPharma ranks better than 61.03% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-09), ABVC BioPharma's 3-1 Month Momentum % is -5.63%.
The industry rank for ABVC BioPharma's 3-1 Month Momentum % or its related term are showing as below:
ABVC's 3-1 Month Momentum % is ranked better than 61.03% of 1378
companies
in the Biotechnology industry
Industry Median: -11.025
vs ABVC: -5.63
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ABVC BioPharma 3-1 Month Momentum % Related Terms
ABVC vs GRCE, ELOX, INMB: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, ABVC BioPharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABVC BioPharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ABVC BioPharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ABVC BioPharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABVC BioPharma (ABVC) has a 3-1 Month Momentum % of -5.63% as of Jul. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ABVC BioPharma and its competitors. According to the industry distribution chart, ABVC BioPharma ranks #537 out of 1378 companies in the Biotechnology industry, placing it in the top 39%.
Is ABVC BioPharma's 3-1 Month Momentum % too high?
ABVC BioPharma's current 3-1 Month Momentum % is -5.63%. Based on the distribution chart, ABVC BioPharma ranks #537 out of 1378 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's 3-1 Month Momentum % compare to GRCE and ELOX?
According to the Biotechnology industry distribution chart, ABVC BioPharma ranks #537 out of 1378 companies for 3-1 Month Momentum %. This puts ABVC BioPharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on ABVC BioPharma and its competitors. ABVC BioPharma's current 3-1 Month Momentum % is -5.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $2.01 — trading 131% above its estimated fair value. The current 3-1 Month Momentum % is -5.63%. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current 3-1 Month Momentum % is -5.63% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABVC BioPharma (ABVC) Overvalued in 2026?
Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued.
The current stock price of $2.01 is trading 131% above its estimated GF Value™ of $0.87.
GuruFocus considers ABVC BioPharma to be Significantly Overvalued.
Key valuation signals for ABVC:
3-1 Month Momentum %: -5.63%
GF Value™: $0.87 vs. price of $2.01 (131% above fair value)
No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score
Get the complete analysis for ABVC
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABVC has been successfully added to your 